Odelniqva (Dapagliflozin)

Odelniqva (dapagliflozin) is an SGLT2‑inhibitor used in the management of metabolic disorders that affect glucose handling.

• Type 2 diabetes mellitus: improves glycaemic control when added to diet, exercise and other antidiabetic agents.
• Heart failure with reduced ejection fraction: reduces risk of cardiovascular death and hospitalization.
• Chronic kidney disease (CKD) in adults: slows progression of renal function decline.
• Cardiovascular risk reduction: lowers incidence of major adverse cardiovascular events in high‑risk patients.
• Adjunct to lifestyle therapy: assists in weight management as part of a comprehensive diabetes plan.

• Dapagliflozin selectively inhibits the sodium‑glucose co‑transporter‑2 (SGLT2) located in the proximal renal tubules. By blocking SGLT2, it reduces renal glucose reabsorption, increasing urinary glucose excretion and lowering plasma glucose levels. The resulting osmotic diuresis also contributes to modest reductions in blood pressure and body weight, supporting its cardiovascular and renal benefits.

Odelniqva may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Genital mycotic infection: more frequent in women and uncircumcised men.
• Urinary tract infection: symptoms include dysuria and increased frequency.
• Increased urination: due to osmotic diuresis.
• Thirst or dry mouth: related to fluid loss.
• Mild hypotension: especially after initiation or dose escalation.
• Elevated LDL‑cholesterol: modest rise observed in lipid panels.

Serious or Rare Side Effects

• Ketoacidosis (euglycaemic): metabolic acidosis with normal or mildly elevated glucose.
• Severe dehydration: can lead to acute kidney injury.
• Fournier's gangrene: necrotizing fasciitis of the perineum, a medical emergency.
• Acute kidney injury: rapid decline in renal function.
• Severe hypersensitivity reactions: including angioedema and anaphylaxis.
• Bone fracture: rare reports of increased fracture risk.

Before initiating Odelniqva, clinicians should assess patient suitability and monitor for specific safety concerns.

• Renal function: evaluate eGFR; avoid if severely impaired.
• Volume status: ensure adequate hydration to reduce hypotension risk.
• Electrolytes: monitor serum potassium and sodium periodically.
• Cardiovascular status: caution in patients with low blood pressure or on diuretics.
• Pregnancy and lactation: avoid use; insufficient safety data.
• Concomitant SGLT2 inhibitors: do not combine with other agents of the same class.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Dapagliflozin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Loop or thiazide diuretics: may exacerbate dehydration and hypotension.
• Insulin or insulin secretagogues: increase risk of hypoglycaemia.
• Strong CYP3A4 inducers (e.g., rifampicin): reduce dapagliflozin exposure.

Moderate Interactions (Monitor Closely)

• ACE inhibitors/ARBs: additive blood‑pressure‑lowering effect.
• NSAIDs: may impair renal function when combined.
• Anticoagulants: monitor for changes in bleeding risk.
• Lipid‑lowering agents: occasional modest rise in LDL‑cholesterol.
• Alcohol: enhances diuretic effect and may worsen hypotension.